Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CNMD 
CONMED Corporation (CNMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: CNMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $61
1 Year Target Price $61
| 0 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.08% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.64B USD | Price to earnings Ratio 14.94 | 1Y Target Price 61 |
Price to earnings Ratio 14.94 | 1Y Target Price 61 | ||
Volume (30-day avg) 6 | Beta 1.19 | 52 Weeks Range 45.83 - 77.23 | Updated Date 09/12/2025 |
52 Weeks Range 45.83 - 77.23 | Updated Date 09/12/2025 | ||
Dividends yield (FY) 1.48% | Basic EPS (TTM) 3.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.31% | Operating Margin (TTM) 10.62% |
Management Effectiveness
Return on Assets (TTM) 4.03% | Return on Equity (TTM) 11.69% |
Valuation
Trailing PE 14.94 | Forward PE 27.03 | Enterprise Value 2521005750 | Price to Sales(TTM) 1.23 |
Enterprise Value 2521005750 | Price to Sales(TTM) 1.23 | ||
Enterprise Value to Revenue 1.9 | Enterprise Value to EBITDA 10.3 | Shares Outstanding 30955000 | Shares Floating 30676368 |
Shares Outstanding 30955000 | Shares Floating 30676368 | ||
Percent Insiders 0.58 | Percent Institutions 114.87 |
Upturn AI SWOT
CONMED Corporation
Company Overview
History and Background
CONMED Corporation was founded in 1970 and has evolved from a small medical device manufacturer to a global surgical medical technology company. Key milestones include strategic acquisitions and expansion into diverse surgical specialties.
Core Business Areas
- Orthopedics: Provides a comprehensive suite of products for orthopedic surgical procedures, including arthroscopic instrumentation, powered surgical instruments, and tissue repair systems.
- General Surgery: Offers a broad range of surgical devices and equipment used in various general surgery procedures, focusing on minimally invasive techniques. This includes advanced surgical energy and endosurgical solutions.
- Advanced Surgical: Focused on surgical energy and smoke evacuation systems.
Leadership and Structure
CONMED is led by a CEO and executive team, with a board of directors overseeing governance. The organizational structure is divided into business units based on product lines and geographic regions.
Top Products and Market Share
Key Offerings
- Arthroscopic Solutions: CONMED offers a range of arthroscopic solutions, including powered resection devices, fluid management systems, and visualization tools. Competitors include Stryker, Smith & Nephew, and Arthrex. Market share is estimated at ~10-15% of the arthroscopy market. Estimated revenue is around $350M.
- Surgical Energy: CONMED's surgical energy portfolio includes electrosurgical generators, handpieces, and accessories used to cut, coagulate, and seal tissue. Competitors include Medtronic, Johnson & Johnson (Ethicon), and Bovie Medical. CONMED market share is between 10-15%. Revenue is around $200M.
- Endoscopic Technologies: CONMED provides a portfolio of endosurgical products like the AirSeal system. Competitors include Olympus, Stryker, and Karl Storz. Revenue is around $100M.
Market Dynamics
Industry Overview
The surgical medical device industry is characterized by innovation, regulatory scrutiny, and increasing demand for minimally invasive procedures. Growth is driven by an aging population, technological advancements, and expanding access to healthcare.
Positioning
CONMED occupies a mid-tier position in the surgical medical device market, focusing on specific niches within orthopedics and general surgery. Competitive advantages include a diverse product portfolio, strong customer relationships, and a focus on innovation.
Total Addressable Market (TAM)
The total addressable market for surgical devices is estimated at over $50 billion. CONMED, with its diverse product offerings, is positioned to capture a portion of this market, focusing on specific niches within orthopedics and general surgery.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio
- Strong customer relationships
- Focus on innovation
- Established distribution network
- Global presence
Weaknesses
- Smaller market share compared to industry leaders
- Dependence on acquisitions for growth
- Exposure to regulatory risks
- Limited brand recognition compared to competitors
Opportunities
- Expanding into emerging markets
- Developing new minimally invasive technologies
- Acquiring complementary businesses
- Partnering with hospitals and healthcare providers
- Increase the number of products utilizing artificial intelligence.
Threats
- Increased competition from larger medical device companies
- Price pressures from healthcare providers
- Changes in healthcare regulations
- Economic downturns impacting hospital budgets
- Product liability claims
Competitors and Market Share
Key Competitors
- STRY (Stryker Corporation)
- ZBH (Zimmer Biomet Holdings, Inc.)
- BSX (Boston Scientific Corporation)
- JNJ (Johnson & Johnson)
- MDT (Medtronic plc)
Competitive Landscape
CONMED faces intense competition from larger, more established medical device companies. To compete effectively, CONMED focuses on innovation, customer service, and strategic acquisitions in niche markets.
Major Acquisitions
In2Bones Global, Inc.
- Year: 2022
- Acquisition Price (USD millions): 145
- Strategic Rationale: Expanded CONMED's portfolio in the extremity orthopedics market, providing innovative solutions for hand, wrist, foot, and ankle procedures.
Biorez, Inc
- Year: 2022
- Acquisition Price (USD millions): 85
- Strategic Rationale: Expanded CONMED's sports medicine portfolio, with new BioBrace implant for soft tissue repair.
Growth Trajectory and Initiatives
Historical Growth: CONMED has grown both organically and through acquisitions, with revenue increasing steadily over the past decade. However, profitability has been inconsistent.
Future Projections: Analyst estimates project moderate revenue growth in the coming years, driven by new product launches and expansion into emerging markets.
Recent Initiatives: Recent initiatives include the launch of new surgical energy platforms and strategic acquisitions to expand the product portfolio.
Summary
CONMED is a mid-sized surgical device company with a diverse product portfolio and a focus on innovation. While it faces intense competition, strategic acquisitions and expansion into niche markets provide growth opportunities. Profitability can be inconsistent. CONMED should prioritize maintaining positive cash flow and managing debt effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Analyst Reports (e.g., from Yahoo Finance, MarketWatch, and Bloomberg)
- Industry Reports (e.g., from EvaluateMedTech, Mordor Intelligence)
Disclaimers:
This analysis is based on publicly available information and analyst estimates, which are subject to change. The information provided is not financial advice and should not be used as the sole basis for investment decisions. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CONMED Corporation
Exchange NYSE | Headquaters Largo, FL, United States | ||
IPO Launch date 1987-07-23 | President, CEO & Director Mr. Patrick J. Beyer | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3900 | Website https://www.conmed.com |
Full time employees 3900 | Website https://www.conmed.com | ||
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures in the United States and internationally. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, the company offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention; and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.